Ellen Goldberg
Independent DirectorMs. Ellen Goldberg serves as Director at Castle Biosciences, Inc. since July 16, 2021. She is founder and president of CHORD Consulting, where she works with executives of innovative diagnostics companies to develop and commercialize novel products since 2011. She has focused her career on ground-breaking technologies in life-threatening and life-altering diseases. From 2009 to 2011, she was vice president of marketing at Crescendo Bioscience, where she launched Vectra DA®, a multi-biomarker blood test that enables treatment changes to improve outcomes in rheumatoid arthritis. Prior to Crescendo, she led marketing at Genomic Health, where she launched the Oncotype DX® Breast Cancer Assay, a standard of care test that empowers over 80,000 women annually to make more informed decisions about their treatment, and helped develop tests in colon cancer, prostate cancer and ductal carcinoma in situ (DCIS). She began her career as a strategy consultant with Booz Allen & Hamilton and developed new products at ALZA Corporation. She has a Master of Science in chemistry and a Master of Business Administration from Stanford University and a Bachelor of Science in chemistry from Yale University. She is also a fellow of the Aspen Institute’s Health Innovators Fellowship Program.
Positions
- Company NameCastle Biosciences, Inc.Stock CodeCSTLPositionIndependent DirectorColleagues
- DJDerek J. MaetzoldFounder, CEO, President & Director
- DMDaniel Mark BradburyIndependent Chairman of the Board
- FSFrank StokesCFO & Treasurer
- KMKristen M. OelschlagerChief Operating Officer
- TWTobin W. JuvenalChief Commercial Officer
- CZCamilla ZuckeroVice President of Investor Relations & Corporate Affairs
- GBGordon Bradley ColeIndependent Director
- TPTiffany P. OlsonIndependent Director
